ArticleThe Journal of allergy and clinical immunology2020
Delivery of allergen powder for safe and effective epicutaneous immunotherapy.
Article in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Gamma Delta T Cells in Shrimp Allergy Express a Unique Cytotoxic Cytokine Profile.Clinical and translational allergy · 2026Article
- Next-Generation Allergen-Specific Immunotherapy for Food Allergy.Clinical reviews in allergy & immunology · 2025Review
- Microneedles in Allergy Immunotherapy: the Present and Future.Current allergy and asthma reports · 2025Review
- Transdermal Allergen-Specific Immunotherapy Using a Biodegradable Microneedle Array Patch in a Murine Model of Peanut Anaphylaxis.Allergy, asthma & immunology research · 2025Article
- Co-delivery of targeted hypoallergens and resiquimod powders using silk fibroin microneedles for effective allergen-specific immunotherapy.Theranostics · 2025Article
- Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.Advanced drug delivery reviews · 2024Review
- Microneedle-Mediated Immunization Promotes Lung CD8+ T-Cell Immunity.The Journal of investigative dermatology · 2023Article
- Sustained antigens delivery using composite microneedles for effective epicutaneous immunotherapy.Drug delivery and translational research · 2023Article
- Recent advances in epicutaneous immunotherapy and potential applications in food allergy.Frontiers in allergy · 2023Review
- Innovative delivery systems for epicutaneous immunotherapy.Frontiers in immunology · 2023Review
- Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development.Yonsei medical journal · 2022Review
- Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut.Immunotherapy · 2022Article
- Immunology of allergen immunotherapy.Immunotherapy advances · 2022Review
- New Therapeutic Approaches for Allergy: A Review of Cell Therapy and Bio- or Nano-Material-Based Strategies.Pharmaceutics · 2021Review
- The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy.Frontiers in immunology · 2021Review
- Innovative Systems to Deliver Allergen Powder for Epicutaneous Immunotherapy.Frontiers in immunology · 2021Review
- Monoolein Assisted Oil-Based Transdermal Delivery of Powder Vaccine.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMore effective and safer immunotherapies to manage peanut allergy are in great demand despite extensive investigation of sublingual/oral immunotherapy and epicutaneous immunotherapy (EPIT) currently in the clinics.
objectiveWe sought to develop a powder-laden, dissolvable microneedle array (PLD-MNA) for epidermal delivery of powdered allergens and to evaluate the efficacy of this novel EPIT in peanut-sensitized mice.
methodsPLD-MNA was packaged with a mixture of powdered peanut allergen (PNA), 1,25-dihydroxyvitamin D
resultsPLD-MNA was successfully laden with PNA/VD3/CpG powder and capable of epidermal delivery of most of its content 1 hour after application onto intact mouse skin concomitant with no significant leakage into the circulation or skin irritation. PLD-MNA-mediated EPIT substantially reduced clinical allergy scores to 1 from 3.5 in sham control mice (P < .001) after 6 treatments accompanied by lower levels of PNA-specific IgE and intestinal mucosal mast cells and eosinophils over sham treatments. Moreover, in comparison with allergens administered intradermally, powdered allergens delivered by means of PLD-MNA preferentially attracted immunoregulatory macrophages and stimulated the cells to produce IL-10, TGF-β, or both at the immunization site, which might account for increased numbers of regulatory T-like cells in lymph tissues in association with systemic tolerance. PNA/VD3/CpG-laden PLD-MNA was safe and required only 6 treatments and one fifth of the PNA adjuvant dose, with improved outcomes when compared with 12 conventional intradermal immunotherapies.
conclusionsPLD-MNA holds great promise as a novel, safe, effective, and self-applicable modality to manage IgE-mediated allergies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.